A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the efficacy of Duloxetine vs. placebo on pain as determined by change in the Brief Pain Inventory (BPI) from baseline over 8 weeks of treatment

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Boehringer Ingelheim
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• Major Depressive Disorder according to DSM-IV criteria with at least one previous depressive episode in the patient's medical history

• Painful physical symptoms as measured by the Brief Pain Inventory-Short Form

Exclusion Criteria:

• Any anxiety disorder as a primary diagnosis within the past 6 months (including panic disorder, OCD, PTSD, generalized anxiety disorder and social phobia)

• Any diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders